Patients from elementary and high school with atopic dermatitis (AD), along with their caregivers, were included in a “prospective, single-center, assessor blinded, pragmatic superiority 2-arm randomized controlled trial” which aimed to improve treatment adherence by improving Eczema Area and Severity Index (EASI) scores.
Forty-four patients were split into two groups: the first received Eczema Action Plan (EAP), and the second did not receive EAP.
Results from this study showed that the EAP did decrease EASI scores in patients with AD after a full month post-follow-up and therefore, is a suitable tool in pediatric patients with AD.
Learn more about this study at the Journal of the American Academy of Dermatology.